Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUAVEE vs OSPEMIFENE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DUAVEE is a combination of conjugated estrogens (CE) and bazedoxifene (BZA). CE activates estrogen receptors (ERα and ERβ) to relieve menopausal symptoms; BZA is a selective estrogen receptor modulator (SERM) that antagonizes ER in the endometrium to prevent endometrial hyperplasia.
Ospemifene is a selective estrogen receptor modulator (SERM) that acts as an agonist on estrogen receptors in vaginal tissues, leading to proliferation and maturation of vaginal epithelium, while exhibiting antagonist activity on breast and endometrial tissues.
Moderate to severe vasomotor symptoms due to menopause,Prevention of postmenopausal osteoporosis
Treatment of moderate to severe dyspareunia (painful intercourse) due to vulvar and vaginal atrophy associated with menopause
One tablet (conjugated estrogens 0.45 mg/bazedoxifene 20 mg) orally once daily.
60 mg orally once daily.
Conjugated estrogens: terminal half-life of estrone sulfate is approximately 10-24 hours. Bazedoxifene: terminal half-life is approximately 30 hours. Clinically, steady state is achieved within 7 days for estrogens and 10-14 days for bazedoxifene.
Terminal elimination half-life is approximately 26 hours (range 20–30 hours), supporting once-daily dosing.
Conjugated estrogens are primarily metabolized in the liver via phase II conjugation (sulfation and glucuronidation) by enzymes such as UGT1A1, UGT1A8, UGT1A9, UGT2B7, and SULT1A1. Bazedoxifene undergoes hepatic metabolism via glucuronidation by UGT1A1, UGT1A8, UGT1A9, and UGT2B7, with minimal CYP involvement.
Primarily metabolized via CYP3A4 and CYP2C9, with minor contributions from CYP2C19, CYP2C8, and CYP2B6. Undergoes glucuronidation and sulfation.
Conjugated estrogens are primarily excreted in urine as glucuronide and sulfate conjugates, with approximately 10-15% excreted in feces via biliary elimination. Bazedoxifene is mainly eliminated in feces (85%) with minimal renal excretion (<1% as unchanged drug).
Primarily hepatic metabolism with biliary excretion; < 30% renal elimination as metabolites. Fecal excretion accounts for approximately 70% of total clearance.
Conjugated estrogens: extensive binding to albumin (approximately 80-85%). Bazedoxifene: highly bound (>99%) to albumin and alpha-1-acid glycoprotein.
> 99% bound to serum proteins, primarily albumin.
Conjugated estrogens: Vd approximately 0.5-2 L/kg, indicating distribution into total body water and tissues. Bazedoxifene: Vd approximately 1.2 L/kg, suggesting extensive tissue distribution.
Approximately 4.2 L/kg, indicating extensive tissue distribution.
Conjugated estrogens: oral bioavailability is approximately 30-50% due to first-pass metabolism. Bazedoxifene: absolute oral bioavailability is approximately 6% due to extensive first-pass glucuronidation.
Oral bioavailability is approximately 20–30% due to first-pass metabolism.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). Not studied in severe renal impairment (Cr Cl <15 m L/min) or dialysis.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). Use with caution in Child-Pugh Class A or B; no specific dose adjustment established, but monitor closely.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). No dose adjustment for Child-Pugh Class A or B; use with caution.
Not indicated for use in pediatric patients. Safety and efficacy have not been established.
Not indicated for pediatric use; safety and efficacy not established.
No specific dose adjustment recommended. Higher risk of adverse events (e.g., thromboembolism, stroke) in women >65 years of age; use lowest effective dose for shortest duration.
No specific dose adjustment required; pharmacokinetics similar to younger adults. Monitor for vulvovaginal atrophy and thromboembolic risks.
Estrogen therapy increases the risk of endometrial cancer in women with a uterus. Concomitant use of a progestin or bazedoxifene is required to reduce this risk. Cardiovascular disorders: Estrogen-alone therapy may increase risk of stroke and DVT. Estrogen plus progestin therapy increases risk of MI, stroke, invasive breast cancer, pulmonary emboli, and DVT. DUAVEE is not approved for cardiovascular disease prevention. Breast cancer: Estrogen plus progestin therapy increases risk of invasive breast cancer. Probable dementia: Estrogen plus progestin therapy increases risk in women 65+.
There is an increased risk of endometrial cancer in women with an intact uterus. Use only when necessary and consider periodic endometrial evaluation.
Cardiovascular disorders (stroke, DVT, MI, pulmonary embolism),Malignant neoplasms (endometrial cancer, breast cancer),Gallbladder disease,Hypertriglyceridemia,Fluid retention,Hypocalcemia,Hereditary angioedema,Exacerbation of endometriosis,Exacerbation of asthma, diabetes, migraine, porphyria, SLE, hepatic hemangiomas,Retinal vascular thrombosis
Endometrial cancer risk,Cardiovascular and cerebrovascular events (not evaluated in long-term studies),Venous thromboembolism (potential risk),Breast cancer (long-term safety not established),Use with caution in patients with hepatic impairment
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE),Active or past history of arterial thromboembolism (e.g., stroke, MI),Known protein C, protein S, or antithrombin deficiency or other thrombophilic disorders,Hypersensitivity to any component,Pregnancy
Undiagnosed abnormal genital bleeding,Known or suspected estrogen-sensitive cancer (e.g., breast cancer),Active or history of venous thromboembolism (e.g., deep vein thrombosis, pulmonary embolism),Pregnancy or women who may become pregnant
Grapefruit juice may increase estrogen levels; avoid large amounts. No other significant food interactions. Alcohol may increase risk of liver issues; limit intake.
Take with food to minimize GI side effects. No specific food restrictions; however, avoid grapefruit juice as it may increase drug levels via CYP3A4 inhibition.
DUAVEE (conjugated estrogens/bazedoxifene) is contraindicated in pregnancy. Estrogens may cause fetal harm; first trimester exposure is associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure increases risk of urogenital abnormalities and delayed cognitive development. Bazedoxifene is a selective estrogen receptor modulator; animal studies show embryotoxicity and fetotoxicity at clinically relevant doses.
Ospemifene is contraindicated in pregnancy due to potential fetal harm. In animal studies, it caused fetal malformations (e.g., skeletal abnormalities) and embryo-fetal loss. There are no adequate human data; however, based on its estrogenic and antiestrogenic activity, it may interfere with fetal development. Use is not recommended at any trimester.
Contraindicated during breastfeeding. Estrogens and bazedoxifene are excreted in human milk; M/P ratio not reported. Estrogens may reduce milk production and quality. Potential for adverse effects in nursing infants.
It is unknown whether ospemifene is excreted in human breast milk. No M/P ratio is available. Due to potential serious adverse effects in the nursing infant, breastfeeding is not recommended during treatment and for one week after the last dose.
No dose adjustments applicable; do not use in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are irrelevant due to contraindication.
Ospemifene is contraindicated in pregnancy; therefore, no dosing adjustments are recommended. If pregnancy occurs, therapy should be discontinued. Due to lack of data and potential harm, no alternative dosing during pregnancy is advised.
DUAVEE (conjugated estrogens/bazedoxifene) is indicated for moderate-to-severe vasomotor symptoms and osteoporosis prevention in postmenopausal women with a uterus. Avoid in women with intact uterus who are not on a progestin; bazedoxifene is the progestin component. Contraindicated in women with undiagnosed abnormal genital bleeding, known/suspected pregnancy, breast cancer, estrogen-dependent neoplasia, active DVT/PE, or history of these conditions. Monitor for thromboembolic events. Not for use in women with prior hysterectomy. Discontinue if jaundice or visual disturbances occur.
Ospemifene is a selective estrogen receptor modulator (SERM) indicated for moderate to severe dyspareunia due to vulvar and vaginal atrophy (VVA) in postmenopausal women. It has estrogenic effects on vaginal tissue but antiestrogenic effects on breast and endometrium. Monitor for thromboembolic events; contraindicated in history of VTE or PE. Not for use in women with breast cancer or estrogen-dependent neoplasia. May cause hot flashes and vaginal discharge.
Take DUAVEE once daily with or without food.,This medication is for postmenopausal women with a uterus; it contains both estrogen and a progestin-like drug to protect the uterine lining.,Do not use if you have any unexplained vaginal bleeding, are pregnant, have or have had breast cancer, blood clots, or liver disease.,Report promptly any signs of blood clots (leg pain/swelling, chest pain, sudden shortness of breath) or stroke (sudden headache, vision/speech changes).,DUAVEE may increase risk of gallbladder disease, dementia (if started after age 65), and endometrial hyperplasia if the progestin component fails.,Smoking while on DUAVEE increases risk of blood clots; avoid smoking.,DUAVEE does not prevent heart attack or stroke; in fact, it may increase cardiovascular risk, especially in older women.,Store at room temperature, away from moisture and heat.,If you miss a dose, take it as soon as possible; if almost time for the next dose, skip the missed dose and resume regular schedule. Do not double dose.,You will need regular medical check-ups including mammograms and pelvic exams.
Take one 60 mg tablet daily with food to reduce gastrointestinal upset.,Notify your healthcare provider if you experience unusual vaginal bleeding, breast pain, or lumps.,Seek immediate medical attention for signs of blood clots: chest pain, shortness of breath, leg swelling or pain, sudden severe headache.,Do not use if you have a history of blood clots, breast cancer, or liver disease.,Ospemifene is for non-surgical women postmenopausal; it does not prevent pregnancy or sexually transmitted infections.,Avoid smoking and limit alcohol intake to reduce the risk of blood clots.
No interactions on record
"Ospemifene, a selective estrogen receptor modulator, inhibits the metabolism of thiotepa, an alkylating agent, by competitively inhibiting cytochrome P450 (CYP) 2B6 and potentially other CYP enzymes involved in thiotepa's biotransformation. This leads to increased systemic exposure to thiotepa, elevating the risk of dose-dependent toxicities such as severe myelosuppression (e.g., neutropenia, thrombocytopenia) and mucositis. Clinically, coadministration may require significant thiotepa dose reduction to avoid excessive bone marrow suppression."
"Ospemifene is primarily metabolized by CYP3A4, and thioridazine is a moderate inhibitor of CYP3A4. Coadministration reduces ospemifene clearance, leading to elevated ospemifene serum concentrations, which may increase the risk of dose-dependent adverse effects such as thromboembolic events, hot flashes, and vaginal discharge. This interaction is clinically significant as it may exacerbate the endocrine and cardiovascular side effects of ospemifene."
"Ospemifene, a selective estrogen receptor modulator (SERM), is primarily metabolized by the cytochrome P450 enzyme CYP3A4. Clarithromycin is a potent macrolide antibiotic and a strong inhibitor of CYP3A4. Coadministration of clarithromycin with ospemifene significantly reduces the metabolic clearance of clarithromycin, leading to increased plasma concentrations of clarithromycin. This elevation can potentiate clarithromycin's adverse effects, including QT interval prolongation, cardiac arrhythmias, hepatotoxicity, and gastrointestinal disturbances, particularly in patients with preexisting risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUAVEE vs OSPEMIFENE, answered by our medical review team.
DUAVEE is a Selective Estrogen Receptor Modulator/Estrogen Combination that works by DUAVEE is a combination of conjugated estrogens (CE) and bazedoxifene (BZA). CE activates estrogen receptors (ERα and ERβ) to relieve menopausal symptoms; BZA is a selective estrogen receptor modulator (SERM) that antagonizes ER in the endometrium to prevent endometrial hyperplasia.. OSPEMIFENE is a Selective Estrogen Receptor Modulator (SERM) that works by Ospemifene is a selective estrogen receptor modulator (SERM) that acts as an agonist on estrogen receptors in vaginal tissues, leading to proliferation and maturation of vaginal epithelium, while exhibiting antagonist activity on breast and endometrial tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUAVEE and OSPEMIFENE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUAVEE is: One tablet (conjugated estrogens 0.45 mg/bazedoxifene 20 mg) orally once daily.. The standard adult dose of OSPEMIFENE is: 60 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUAVEE and OSPEMIFENE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUAVEE is classified as Category C. DUAVEE (conjugated estrogens/bazedoxifene) is contraindicated in pregnancy. Estrogens may cause fetal harm; first trimester exposure is associated with congenital anomalies includi. OSPEMIFENE is classified as Category C. Ospemifene is contraindicated in pregnancy due to potential fetal harm. In animal studies, it caused fetal malformations (e.g., skeletal abnormalities) and embryo-fetal loss. There. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.